Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 7/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317189 | 0.88 | PTGDR2 (0.53) | PTGDR2MAP3K14EIF2AK2NR1H2NR1H3 | |
| SCHEMBL2955003 | 0.88 | MAPK14 (0.47) | PTGDR2MAPK14MAP3K14EIF2AK2HTR2A | |
| SCHEMBL2959852 | 0.85 | KIF11 (0.42) | PTGDR2MAP3K14EIF2AK2NR1H2NR1H3 | |
| SCHEMBL2961945 | 0.85 | NR1H2 (0.47) | PTGDR2MAPK14EIF2AK2HTR2AHTR2C | |
| SCHEMBL2958727 | 0.83 | PTGDR2 (0.48) | PTGDR2MAPK14EIF2AK2HTR2AHTR2C | |
| SCHEMBL317159 | 0.83 | NR1H2 (0.55) | PTGDR2MAP3K14EIF2AK2NR1H2NR1H3 | |
| SCHEMBL2961240 | 0.79 | MAP3K14 (0.48) | PTGDR2MAP3K14EIF2AK2HTR2AHTR2C | |
| SCHEMBL317746 | 0.78 | PTGDR2 (0.53) | PTGDR2MAPK14MAP3K14EIF2AK2MAPK1 | |
| SCHEMBL31105587 | 0.76 | MAP3K14 (0.60) | MAP3K14EIF2AK2HTR2AHTR2CHTR7 | |
| SCHEMBL2951882 | 0.76 | KIF11 (0.49) | PTGDR2MAP3K14EIF2AK2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | PTGDR2 429/4885MAPK14 3854/4885MAP3K14 3677/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | PTGDR2 54/4885MAPK14 2477/4885MAP3K14 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.